HAEMONETICS CORP 4
4 · HAEMONETICS CORP · Filed Oct 23, 2015
Insider Transaction Report
Form 4
Davies Kent J
President, Global Markets
Transactions
- Award
Non-qualified Stock Option (Right to Buy)
2015-10-20$31.97/sh+42,967$1,373,655→ 42,967 totalExercise: $31.97From: 2016-10-20Exp: 2022-10-20→ Common Stock (42,967 underlying) - Award
Common Stock
2015-10-20$0.01/sh+9,774$98→ 16,314 total - Award
Performance Shares
2015-10-20+19,549→ 45,960 totalExercise: $0.00From: 2018-09-30Exp: 2018-12-31→ Common Stock (19,549 underlying)
Footnotes (3)
- [F1]Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
- [F2]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- [F3]Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Standard & Poors Health Care Equipment Index. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2015 and September 30, 2018. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).